Back to top
more

CytomX Therapeutics (CTMX)

(Real Time Quote from BATS)

$2.12 USD

2.12
251,273

-0.05 (-2.30%)

Updated Aug 7, 2025 11:14 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

BioDelivery (BDSI) Beats Q4 Earnings Estimates, Stock Up

by Zacks Equity Research

BioDelivery's (BDSI) strong Belubca sales drive the top line. Symproic further boosts revenues. The company expects total revenues to be in the range of $170 - $180 million in 2021.

Zacks Equity Research

CytomX Therapeutics (CTMX) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

CytomX Therapeutics (CTMX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Moving Average Crossover Alert: CytomX Therapeutics (CTMX)

by Zacks Equity Research

CytomX Therapeutics (CTMX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Zacks Equity Research

CytomX Therapeutics (CTMX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 11.11% and 1.95%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CytomX Therapeutics (CTMX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

CytomX Therapeutics (CTMX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

CytomX Therapeutics (CTMX) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

CytomX Therapeutics (CTMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Is CytomX Therapeutics (CTMX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (CTMX) Outperforming Other Medical Stocks This Year?

Benjamin Rains headshot

Find Strong Stocks Ahead of Q2 Earnings Season with this First Profit Screener

by Benjamin Rains

We used our 'First Profit' stock screener to help investors find strong stocks that might be worth looking at in preparation for Q2 earnings season...

Zacks Equity Research

Is CytomX Therapeutics (CTMX) Stock a Solid Choice Right Now?

by Zacks Equity Research

CytomX Therapeutics (CTMX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Equity Research

All You Need to Know About CytomX Therapeutics (CTMX) Rating Upgrade to Strong Buy

by Zacks Equity Research

CytomX Therapeutics (CTMX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for May 4th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.

Zacks Equity Research

CytomX Therapeutics (CTMX) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

CytomX Therapeutics (CTMX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Why CytomX Therapeutics (CTMX) Stock Might be a Great Pick

by Zacks Equity Research

CytomX Therapeutics (CTMX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Equity Research

Here's Why CytomX Therapeutics (CTMX) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does CytomX Therapeutics (CTMX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for April 17th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 17th

Zacks Equity Research

CytomX Therapeutics (CTMX) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

CytomX Therapeutics (CTMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Will CytomX Therapeutics Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor CytomX Therapeutics

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for April 3rd

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 3rd

Zacks Equity Research

CytomX & Astellas Collaborate to Develop Novel Cancer Therapy

by Zacks Equity Research

CytomX (CTMX) and Astellas Pharma sign collaboration agreement to develop novel cancer therapy using CytomX's Probody therapeutic technology platform.

Zacks Equity Research

CytomX Therapeutics (CTMX) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -43.64% and -47.24%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CytomX Therapeutics (CTMX) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

CytomX Therapeutics (CTMX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Will CytomX Therapeutics (CTMX) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -16.36% and -40.34%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: CytomX Therapeutics (CTMX) Q2 Earnings Expected to Decline

by Zacks Equity Research

CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.